Current status of mucins in the diagnosis and therapy of cancer

Satyanarayana Rachagani, Maria P. Torres, Nicolas Moniaux, Surinder Kumar Batra

Research output: Contribution to journalReview article

81 Citations (Scopus)

Abstract

Mucins are the most abundant high molecular weight glycoproteins in mucus. Their nature and glycosylation content dictates the biochemical and biophysical properties of viscoelastic secretions, pointing out an important role in diverse biological functions, such as differentiation, cell adhesions, immune responses, and cell signaling. Mucins are expressed in tubular organs by specialized epithelial cells in the body. Their aberrant expression is well documented in a variety of inflammatory or malignant diseases. From a prognosis point of view, their expression and alterations in glycosylation are associated with the development and progression of malignant diseases. Therefore, mucins can be used as valuable markers to distinguish between normal and disease conditions. Indeed, this alteration in glycosylation patterns generates several epitopes in the oligosaccharide side chains that can be used as diagnostic and/or prognostic markers. Furthermore, these characteristic tumor-associated epitopes are extensively used as appropriate immunotargets of malignant epithelial cells. Therefore, in an effort to detect and treat cancer at the earliest stage possible, mucins are analyzed as potential markers of disease for diagnosis, progression, and for therapeutic purposes. In this review, we focused on the current status of the distribution of mucins in normal and pathologic conditions and their clinical use both in cancer diagnosis and therapeutics treatments.

Original languageEnglish (US)
Pages (from-to)509-527
Number of pages19
JournalBioFactors
Volume35
Issue number6
DOIs
StatePublished - Jan 1 2009

Fingerprint

Mucins
Glycosylation
Neoplasms
Disease Progression
Epitopes
Epithelial Cells
Cell signaling
Therapeutics
Cell adhesion
Oligosaccharides
Cell Adhesion
Tumors
Glycoproteins
Molecular Weight
Molecular weight

Keywords

  • Cancer diagnosis
  • Cancer therapy
  • Mucins

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Clinical Biochemistry

Cite this

Current status of mucins in the diagnosis and therapy of cancer. / Rachagani, Satyanarayana; Torres, Maria P.; Moniaux, Nicolas; Batra, Surinder Kumar.

In: BioFactors, Vol. 35, No. 6, 01.01.2009, p. 509-527.

Research output: Contribution to journalReview article

Rachagani, Satyanarayana ; Torres, Maria P. ; Moniaux, Nicolas ; Batra, Surinder Kumar. / Current status of mucins in the diagnosis and therapy of cancer. In: BioFactors. 2009 ; Vol. 35, No. 6. pp. 509-527.
@article{ca73fa3583eb472689810d8cdabfa12a,
title = "Current status of mucins in the diagnosis and therapy of cancer",
abstract = "Mucins are the most abundant high molecular weight glycoproteins in mucus. Their nature and glycosylation content dictates the biochemical and biophysical properties of viscoelastic secretions, pointing out an important role in diverse biological functions, such as differentiation, cell adhesions, immune responses, and cell signaling. Mucins are expressed in tubular organs by specialized epithelial cells in the body. Their aberrant expression is well documented in a variety of inflammatory or malignant diseases. From a prognosis point of view, their expression and alterations in glycosylation are associated with the development and progression of malignant diseases. Therefore, mucins can be used as valuable markers to distinguish between normal and disease conditions. Indeed, this alteration in glycosylation patterns generates several epitopes in the oligosaccharide side chains that can be used as diagnostic and/or prognostic markers. Furthermore, these characteristic tumor-associated epitopes are extensively used as appropriate immunotargets of malignant epithelial cells. Therefore, in an effort to detect and treat cancer at the earliest stage possible, mucins are analyzed as potential markers of disease for diagnosis, progression, and for therapeutic purposes. In this review, we focused on the current status of the distribution of mucins in normal and pathologic conditions and their clinical use both in cancer diagnosis and therapeutics treatments.",
keywords = "Cancer diagnosis, Cancer therapy, Mucins",
author = "Satyanarayana Rachagani and Torres, {Maria P.} and Nicolas Moniaux and Batra, {Surinder Kumar}",
year = "2009",
month = "1",
day = "1",
doi = "10.1002/biof.64",
language = "English (US)",
volume = "35",
pages = "509--527",
journal = "BioFactors",
issn = "0951-6433",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Current status of mucins in the diagnosis and therapy of cancer

AU - Rachagani, Satyanarayana

AU - Torres, Maria P.

AU - Moniaux, Nicolas

AU - Batra, Surinder Kumar

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Mucins are the most abundant high molecular weight glycoproteins in mucus. Their nature and glycosylation content dictates the biochemical and biophysical properties of viscoelastic secretions, pointing out an important role in diverse biological functions, such as differentiation, cell adhesions, immune responses, and cell signaling. Mucins are expressed in tubular organs by specialized epithelial cells in the body. Their aberrant expression is well documented in a variety of inflammatory or malignant diseases. From a prognosis point of view, their expression and alterations in glycosylation are associated with the development and progression of malignant diseases. Therefore, mucins can be used as valuable markers to distinguish between normal and disease conditions. Indeed, this alteration in glycosylation patterns generates several epitopes in the oligosaccharide side chains that can be used as diagnostic and/or prognostic markers. Furthermore, these characteristic tumor-associated epitopes are extensively used as appropriate immunotargets of malignant epithelial cells. Therefore, in an effort to detect and treat cancer at the earliest stage possible, mucins are analyzed as potential markers of disease for diagnosis, progression, and for therapeutic purposes. In this review, we focused on the current status of the distribution of mucins in normal and pathologic conditions and their clinical use both in cancer diagnosis and therapeutics treatments.

AB - Mucins are the most abundant high molecular weight glycoproteins in mucus. Their nature and glycosylation content dictates the biochemical and biophysical properties of viscoelastic secretions, pointing out an important role in diverse biological functions, such as differentiation, cell adhesions, immune responses, and cell signaling. Mucins are expressed in tubular organs by specialized epithelial cells in the body. Their aberrant expression is well documented in a variety of inflammatory or malignant diseases. From a prognosis point of view, their expression and alterations in glycosylation are associated with the development and progression of malignant diseases. Therefore, mucins can be used as valuable markers to distinguish between normal and disease conditions. Indeed, this alteration in glycosylation patterns generates several epitopes in the oligosaccharide side chains that can be used as diagnostic and/or prognostic markers. Furthermore, these characteristic tumor-associated epitopes are extensively used as appropriate immunotargets of malignant epithelial cells. Therefore, in an effort to detect and treat cancer at the earliest stage possible, mucins are analyzed as potential markers of disease for diagnosis, progression, and for therapeutic purposes. In this review, we focused on the current status of the distribution of mucins in normal and pathologic conditions and their clinical use both in cancer diagnosis and therapeutics treatments.

KW - Cancer diagnosis

KW - Cancer therapy

KW - Mucins

UR - http://www.scopus.com/inward/record.url?scp=73349125438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349125438&partnerID=8YFLogxK

U2 - 10.1002/biof.64

DO - 10.1002/biof.64

M3 - Review article

VL - 35

SP - 509

EP - 527

JO - BioFactors

JF - BioFactors

SN - 0951-6433

IS - 6

ER -